TRCT
LENZ

Tower Research Capital (TRC)’s LENZ Therapeutics LENZ Stock Holding History

Tower Research Capital (TRC)’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.06K Sell
444
-1,255
-74% -$17.6K ﹤0.01% 4231
2025
Q4 		$27.2K Buy
1,699
+234
+16% +$6.82K ﹤0.01% 2872
2025
Q3 		$68.2K Buy
1,465
+60
+4% +$2.21K ﹤0.01% 2282
2025
Q2 		$41.2K Buy
1,405
+477
+51% +$13K ﹤0.01% 3130
2025
Q1 		$23.9K Sell
928
-932
-50% -$23K ﹤0.01% 2803
2024
Q4 		$53.7K Buy
1,860
+1,151
+162% +$35.1K ﹤0.01% 2504
2024
Q3 		$16.8K Sell
709
-157
-18% -$3.48K ﹤0.01% 3345
2024
Q2 		$15K Buy
866
+415
+92% +$7.25K ﹤0.01% 3926
2024
Q1 		$10.1K Sell
451
-195
-30% -$4.05K ﹤0.01% 3748
2023
Q4 		$11.8K Buy
646
+12
+2% +$198 ﹤0.01% 4097
2023
Q3 		$11K Buy
634
+178
+39% +$3.1K ﹤0.01% 4051
2023
Q2 		$8.3K Sell
456
-232
-34% -$4.63K ﹤0.01% 4449
2023
Q1 		$11K Buy
688
+386
+128% +$6.24K ﹤0.01% 4280
2022
Q4 		$7K Sell
302
-624
-67% -$14.5K ﹤0.01% 4636
2022
Q3 		$21K Buy
926
+824
+808% +$19.6K ﹤0.01% 3913
2022
Q2 		$2K Sell
102
-295
-74% -$6.58K ﹤0.01% 5623
2022
Q1 		$14K Sell
397
-455
-53% -$28.5K ﹤0.01% 3929
2021
Q4 		$74K Buy
852
+755
+778% +$62.6K ﹤0.01% 2452
2021
Q3 		$11K Buy
+97
New +$14.4K ﹤0.01% 4269

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Tower Research Capital (TRC)'s LENZ Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its LENZ Therapeutics (LENZ) stake by 74% in Q1 2026, selling an estimated $17.6K and leaving 444 shares worth $4.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4231.

Tower Research Capital (TRC) first reported a position in LENZ in Q3 2021 and has held it in 19 quarters since. The position peaked at $74K in Q4 2021. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Tower Research Capital (TRC) held 444 shares of LENZ Therapeutics worth $4.06K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,255 LENZ Therapeutics shares in Q1 2026, an estimated $17.6K.
  • LENZ Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4231 holding.
  • Tower Research Capital (TRC) first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s LENZ Therapeutics position peaked at $74K in Q4 2021.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.